Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
90-95% bound to alpha-1-acid glycoprotein and albumin.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Not available.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE vs ADDERALL 30, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.